Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 10491-10500 Newer>

The Motley Fool November 1, 2005 Stephen D. Simpson	Disruptions Don't Derail Genesee Not that you'd really know it from the financial reports or the strength of the stock, but the third quarter was actually a challenging one for short-line rail operator Genesee & Wyoming.
The Motley Fool November 1, 2005 Seth Jayson	Colgate: Another Boring Success All systems are go at Colgate Palmolive. Just don't ask for excitement. Companies of this size aren't spectacular growth opportunities just waiting for exploitation, but they do provide robust downside protection.
The Motley Fool November 1, 2005 Stephen D. Simpson	Defense the Best Offense at Oshkosh Returns on capital have improved, but the quarter-to-quarter volatility is a cause for concern at this specialized truck manufacturer.
The Motley Fool November 1, 2005 Rich Duprey	Patents Flatter Color Kinetics The LED lighting provider has a record quarter and says recent rulings will help in future quarters. In spite of competitor complaints, solid-state lighting appears to be a growth industry with lots of potential, and this company appears to be leading the way.
The Motley Fool November 1, 2005 Stephen D. Simpson	BJ Thrives on Pressure So long as demand for drilling stays strong, so too will demand for BJ's pressure pumping services. While I wouldn't plan on holding this cyclical company for the long haul, near-term earnings power and interest in the energy markets could still make for further gains.
The Motley Fool November 1, 2005 Stephen D. Simpson	Chesapeake All Gassed Up Now the No. 3 gas player in the U.S., Chesapeake still sees growth opportunities. Investors, take note.
The Motley Fool November 1, 2005 Rich Duprey	Eisai's Good Medicine The Japanese pharmaceutical reports record sales and earnings on the strength of its Alzheimer's treatment. Sales and profit growth have caused Eisai's share price to surge by about 33% since the beginning of the year.
The Motley Fool November 1, 2005 Brian Gorman	Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD.
The Motley Fool November 1, 2005 Stephen D. Simpson	Belly Up to Barr Though not cheap, this is a high-quality generic drug company. However, investors must do their own due diligence and decide for themselves whether today's price offers enough margin of safety for a sound investment.
The Motley Fool November 1, 2005 Seth Jayson	Cherokee Shows You the Money Yet another dividend lift makes lean clothing brand licensor Cherokee well worth another look.
<Older 10491-10500 Newer> Return to current articles.